Charles River Laboratories International, Inc.

“We are a leading, full service, non-clinical global drug development partner with a mission to create healthier lives.”

“We are a leading, full service, non-clinical global drug development partner... We currently operate in over 120 sites and in over 20 countries worldwide, which numbers exclude certain Insourcing Solutions (IS) sites.”

“Our three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).”

“We have three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing).”

“Our Biologics Solutions (Biologics) business is comprised of our Biologics Testing Services business and CDMO business.”

“Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world.”

“Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world.”

“We perform specialized testing of biologics frequently outsourced by pharmaceutical and biotechnology companies globally”

“We continue to maintain our position as a global leader in the production and sale of the most widely used research models, including over 140 different stocks and strains of purpose-bred rodents.”

“Our Accugenix® global lab network is the premier provider of ISO17025-accredited contract microbial identification services.”

“In 2023, we launched Endosafe® Trillium®, our animal-free recombinant test for endotoxin detection.”

“Using the Celsis® protocol and instrumentation, clients can detect contamination within 4 to 7 days and make objective product release decisions.”

“Our Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing) as well as contract development and manufacturing products and services (CDMO).”

“Our RMS reportable segment includes the products and services offered within Research Models, Research Model Services, and Cell Solutions.”

“We further design and provide viral clearance programs according to GLP at our German facility and cGMP at our U.S. facility for Phase I, II and III human clinical studies as well as for market authorization.”

“In 2025, RMS accounted for 21.1% of our total revenue and approximately 4,140 of our employees, including approximately 190 science professionals with advanced degrees.”

“Our Manufacturing businesses produce FDA regulated endotoxin test kits at an FDA registered facility.”

“Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business.”

“our CDMO operations require various raw materials supplied primarily by third parties... the raw materials and other items may only be supplied by a limited number of suppliers or in limited quantities.”

“In fiscal 2025, we hired over 2,600 people and our voluntary turnover for all employees was approximately 10.1%.”

“The purchase price of KF was $510.0 million, of which $335.0 million was paid up-front, with the remaining $175.0 million deferred until the completion of certain post-close conditions.”

“we have exercised our option to acquire the remaining 79% equity interest in PathoQuest SAS (PathoQuest) for €51.6 million (or approximately $60 million based on current exchange rates)”

“we completed our acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of NHPs located in Mauritius, resulting in a 90% controlling interest.”

“Endosafe® Trillium® utilizes three biological proteins, which we believe provides superior accuracy and testing outcomes to competitors’ single-protein recombinant alternatives, as well as equivalence to LAL-based testing method.”

“It is estimated that the market for regulated safety assessment services is 60% outsourced or more, while emerging growth areas such as discovery and certain research model services are currently believed to be less outsourced.”

“we expect to close or consolidate approximately 12 additional sites over the next two years, principally focused on the DSA and RMS segments”

“we will focus on strategic initiatives to strengthen our leading scientific portfolio within our core markets through strategic acquisitions, partnerships, internal investments, and divestments of certain non-core assets, which represent approximately 7% of our 2025 revenue.”

“these actions are expected to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026, of which more than $175 million benefitted fiscal 2025. ... We incurred restructuring charges of $99.8 million and $107.0 million during the fiscal years 2025 and 2024, respectively.”

“Since we do not expect to pay any cash dividends for the foreseeable future, our shareholders will benefit from an investment in our common stock only if it appreciates in value.”

“The Animal Welfare Act (AWA) governs the care and use of animals used for research in the U.S. other than laboratory rats, mice and fish bred for use in research.”

“GLP compliance is required by such regulatory agencies as the FDA, European Medicines Agency, Medicines and Healthcare Products Regulatory Agency in the United Kingdom (U.K.), Health Products Regulatory Authority in Ireland, Health Canada”

“In November 2025, the Company received USFWS CITES clearance to import Cambodian NHPs into the United States, and has resumed such activity.”

“We believe our aggregate backlog as of any date is not necessarily a meaningful indicator of our future results for a variety of reasons.”

“Many of our agreements, including those which underlie our strategic relationships with some of our more significant clients, allow for termination or reduction in scope with little or no notice.”

“the NIH announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect overhead... allowing nearly $800 million in federal grants to be terminated.”

“the putative securities class action lawsuit filed against us and certain current/former officers on May 19, 2023”

“As of the date of this filing, to our knowledge, we have not experienced a material information security breach or material cybersecurity incident since an event in 2019.”

“Regulatory monitoring authorities such as the FDA, Medicines and Healthcare Products Regulatory Agency and OECD countries have indicated a continued emphasis on the management of electronic records and signatures generated by computerized systems to ensure data integrity.”

“Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business.”

“Our business could be adversely affected by any significant decrease in drug R&D expenditures by pharmaceutical and biotechnology companies... Additionally, our business is exposed to the risk of credit losses, which arises from our extension of credit to clients.”